Please login to the form below

CAR-Ts

This page shows the latest CAR-Ts news and features for those working in and with pharma, biotech and healthcare.

Allogene raises $324m from record-breaking IPO for off-the shelf CAR-Ts

Arie Belldegrun (left) and David Cheng . Belldegrun and Cheng they can go one better than these first generation autologous CAR-Ts. ... Allogene is among a number of companies who want to leapfrog the leaders with allogenic or 'off the shelf' CAR-Ts.

Latest news

Gilead strikes deal with NHS England on CAR-T Yescarta

The biggest challenge of CAR-Ts is in the complex manufacturing process, which requires a patient’s own T cells to be extracted, then modified genetically in a laboratory to carry ... Integral to providing CAR-Ts is the setting up of these new
Kymriah rejected in DLBCL - but NICE wants to keep talking about cost effectiveness

This is far from surprising – NICE has already come to the same preliminary conclusion about its CAR-T rival, Gilead’s Kymriah in DLBCL on 28 August. ... One final factor is the complexity and difficulty of producing CAR-Ts: Novartis has indicated
London cancer hub launched by Cancer Research UK

London cancer hub launched by Cancer Research UK. Specialist centres unite to collaborate on immunotherapies such as CAR-T. ... Francis Crick Institute – bringing together researchers who will collaborate on cancer biotherapeutics including
Novartis and Gilead's rival CAR-Ts approved in Europe, but supply capacity in question

Novartis and Gilead's rival CAR-Ts approved in Europe, but supply capacity in question. ... Both Novartis and Gilead are setting up new production facilities to help meet the demand for their CAR-Ts.
It’s a no for Yescarta, says NICE on heels of EU approval

CAR T cell therapy uses a patient’s own genetically modified immune cells to target their cancer. ... If we’re going to see CAR T therapy widely available on the NHS, we need to find ways to reduce the costs.

More from news
Approximately 6 fully matching, plus 12 partially matching documents found.

Latest Intelligence

Cancer immunotherapy: What's on the horizon?

antigen receptor T-cell (CAR-T) therapies from Novartis and Gilead gained regulatory approval in 2017 for acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL) after showing remarkable ... The CAR-Ts have transformed the treatment
Immuno-oncology is fundamentally changing what value means, but how quickly can the pharma marketing, educational and service model change to reflect that?

It follows that the next generation of relationship holders, representing very expensive but ultra-personalised medicines like CAR-Ts (which are based on patients’own cells) will be concierge-like, offering
Bluebird Bio: on the cusp of a gene therapy revolution

Analysts think bb2121 could gain approval by 2020 and hit peak sales of $5bn, leading a crowded CAR-T field in the disease. ... This is especially likely around its multiple myeloma candidate bb2121, where competition will be fierce from rival multiple
30 Women Leaders in UK Healthcare

Current projects include developing antibodies for use as cancer imaging agents, antibody drug conjugates, chimeric antigen receptor therapies (CAR-Ts) and nano-medicines.
Pharma deals during June 2014

Similarly, Pfizer signed up with the French company Cellectis for its CAR-T platform which uses chimeric antigen receptors to reprogramme T-cells to target cancers. ... Instead of arriving at a personalised solution by harvesting individual patient's

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Medical Strategic Director, Healthcare Advertising Agency: Salary TBC

Lead Medical Copywriter, Healthcare Brand Communications, London: Excellent package

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Project / Account Manager (Medical Education): Salary TBC

Account Director – Global Healthcare PR: Salary TBC

Account Manager, Healthcare Communications: £32, 000 - £40, 000 benefits

Senior Account Manager - Med Comms: Highly Competitive Salary &Benefits

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Associate Medical Director: Highly Competitive

Scientific Team Lead: Competitive Salary

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Account Director - Digital: Great salary and benefits

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Senior Account Executive – Medical Communications: Salary TBC

Account Director: Negotiable

Account Manager- Manchester, Macclesfield or Glasgow: Negotiable

Director Healthcare PR Communications: Salary TBC

Scientific Director: Highly Competitive Salary &Benefits

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Account Manager, Healthcare Advertising: Salary TBC

Director – Head of Public Affairs: Neg

Senior Medical Writer (Remote Working): Competitive Salary Offered

Experienced Editor, London, Medical Communications: Competitive package

Editorial Director – Medical Education: Neg

Associate Medical Director: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies: Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?: Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds: A vision of Paris as Europe's leading hub for life sciences innovation...